Denosumab boosts bone mineral in prostate cancer
A phase III trial demonstrated that denosumab can reduce fracture risk in men with nonmetastatic prostate cancer undergoing androgen deprivation therapy, Amgen announced.
A phase III trial demonstrated that denosumab can reduce fracture risk in men with nonmetastatic prostate cancer undergoing androgen deprivation therapy, Amgen announced.
In the HALT study, 1,468 men undergoing ADT for nonmetastatic prostate cancer and treated with denosumab (60 mg) experienced a 62% reduction in the risk of suffering a new vertebral fracture at 36 months compared to placebo. Patients experienced a 6.7% increase in BMD at the lumbar spine at 24 months compared to those receiving placebo. Increases in BMD at the lumbar spine were observed as early as one month after starting treatment with denosumab and continued to increase throughout the study (N Engl J Med online, August 11, 2009).
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
